bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath Lung
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases and topically delivered therapeutics for squamous and basal cell skin cancers, today reported...
Business Wire
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath Lung
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents...
Business Wire
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
Zacks
bioAffinity Technologies and Pictor, Inc. Partner to Develop and Commercialize bioAffinitys Diagnostics for Asthma and COPD
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of bioAffinity...
Business Wire
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
Zacks
bioAffinity Technologies Quarterly CyPath Lung Sales Double to New Record as Commercial Momentum Continues
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced continued acceleration in commercial sales for CyPath Lung, its noninvasive lung...
Business Wire
bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, will present preclinical findings for a novel therapeutic approach that uses small interfering RNAs (siRNAs) that kill squamous and basal skin cancer...
Business Wire
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering PR Newswire JERSEY CITY, N.J., June 18, 2026 JERSEY CITY,N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a...
PR Newswire
bioAffinity Technologies Announces Closing of $3.2 Million Offering
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today announced the closing of its previously announced public offering of securities as described...
Business Wire
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering PR Newswire JERSEY CITY, N.J., June 17, 2026 JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a...
PR Newswire